OptimizeRx Corp. (OPRX) – What Are Investment Firms Thinking About This Stock?

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $11.57.

A number of analysts have recently issued reports on OPRX shares. B. Riley Financial increased their price objective on shares of OptimizeRx from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, September 29th. Citigroup restated a “market outperform” rating on shares of OptimizeRx in a research note on Friday, August 14th. UBS Group set a $11.00 target price on shares of OptimizeRx in a research note on Friday, August 14th. Weiss Ratings raised shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, August 25th. Finally, Stifel Nicolaus set a $12.00 target price on shares of OptimizeRx in a report on Thursday, August 13th.

OptimizeRx Price Performance

NASDAQ OPRX opened at $8.29 on Thursday. OptimizeRx has a 12 month low of $4.54 and a 12 month high of $22.25. The stock has a market cap of $156.15 million, a price-to-earnings ratio of 36.05 and a beta of 1.26. The company’s 50 day moving average is $7.88 and its two-hundred day moving average is $6.62. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.05. The business had revenue of $20.50 million for the quarter, compared to the consensus estimate of $20.20 million. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. As a group, research analysts anticipate that OptimizeRx will post 0.49 earnings per share for the current year.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently bought and sold shares of OPRX. Rice Hall James & Associates LLC lifted its position in shares of OptimizeRx by 1.9% in the first quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after acquiring an additional 11,247 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of OptimizeRx by 22.3% in the first quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after acquiring an additional 102,661 shares during the period. AWM Investment Company Inc. bought a new position in shares of OptimizeRx in the second quarter worth about $1,375,000. Renaissance Technologies LLC grew its position in shares of OptimizeRx by 633.2% during the first quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock worth $1,362,000 after purchasing an additional 187,278 shares in the last quarter. Finally, Segall Bryant & Hamill LLC purchased a new stake in shares of OptimizeRx during the first quarter worth about $1,185,000. 76.47% of the stock is owned by institutional investors.

About OptimizeRx

OptimizeRx Corporation is a digital health company that provides technology and communication solutions for the life sciences and healthcare industries. Its platform connects pharmaceutical and biotechnology companies with healthcare providers and patients through digital channels integrated into electronic health records, electronic prescribing systems and other clinical workflows.

The company’s solutions support activities such as delivering treatment information, patient savings and affordability offers, medication adherence programs, and other communications intended to help patients access and remain on prescribed therapies.